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Background: Mesenchymal stem cells (MSCs) are known to be capable of suppressing inflammatory responses.
We previously reported that intra-abdominal implantation of bone marrow-derived MSCs (BM-MSCs) sheet by
laparotomy attenuated angiotensin II (AngII)-induced aortic aneurysm (AA) growth in apolipoprotein E-deficient
(apoE−/−) mice through anti-inflammation effects. However, cell delivery by laparotomy is invasive; we here
demonstrated the effects of multiple intravenous administrations of BM-MSCs on AngII-induced AA formation.
Methods: BM-MSCs were isolated from femurs and tibiae of male apoE−/− mice. Experimental AA was induced by
AngII infusion for 28 days in apoE−/− mice. Mice received weekly intravenous administration of BM-MSCs (n=12) or
saline (n=10). After 4 weeks, AA formation incidence, aortic diameter, macrophage accumulation, matrix
metalloproteinase (MMP)’ activity, elastin content, and cytokines were evaluated.
Results: AngII induced AA formation in 100% of the mice in the saline group and 50% in the BM-MSCs treatment
group (P < 0.05). A significant decrease of aortic diameter was observed in the BM-MSCs treatment group at ascending
and infrarenal levels, which was associated with decreased macrophage infiltration and suppressed activities of MMP-2
and MMP-9 in aortic tissues, as well as a preservation of elastin content of aortic tissues. In addition, interleukin (IL)-1β,
IL-6, and monocyte chemotactic protein-1 significantly decreased while insulin-like growth factor-1 and tissue inhibitor
of metalloproteinases-2 increased in the aortic tissues of BM-MSCs treatment group.
Conclusions: Multiple intravenous administrations of BM-MSCs attenuated the development of AngII-induced AA in
apoE−/− mice and may become a promising alternative therapeutic strategy for AA progression.
Keywords: Mesenchymal stem cells, Aortic aneurysm, Cell transplantation, Chronic inflammation,
Matrix metalloproteinaseBackground
Aortic aneurysm (AA) is a common life-threatening disease
and its prevalence is increasing with the ageing society [1].
For large AAs, which have a high risk of rupture, surgical
treatment by open or endovascular repair is generally
recommended. However, the great majority of AA is small
and below the threshold for immediate surgical repair.
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reproduction in any medium, provided the orlong term survival advantages [2,3]. On the other hand,
there are few therapeutic strategies for surgically unsuit-
able patients who show high risk for surgery. Therefore,
the development of a non-surgical therapeutic approach
for treating AA is needed. With advances in vascular
biology and understanding of the mechanism of AA forma-
tion at the cellular and molecular levels, several pharmaco-
logical agents, including statins, β-blockers, ACE-inhibitors,
anti-inflammatory agents, and antibiotics, have been re-
ported to limit AA progression in experimental models and
some agents have undergone clinical trials [4,5]. However,
they showed modest benefits in large clinical trials [5,6],This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion of AA progression.
The pathogenesis of AA is characterized by chronic
inflammation in the aortic wall with accumulation of
macrophages and degradation of extracellular matrix with
increased matrix metalloproteinases (MMPs). Infiltrated
inflammatory cells such as macrophages, and lymphocytes
cause activation of matrix metalloproteinases, particularly
MMP-2 and MMP-9, resulting in the degradation of
both collagen and its associated collagenous matrix, along
with elastin fragmentation and smooth muscle cell (SMCs)
apoptosis, which contribute prominently to AA develop-
ment [7-9]. The positive correlation between inflammatory
infiltrates and aneurysmal enlargement [10], as well as
regression of established AA by limiting proinflammatory
signaling in mice [11], suggest the important role of in-
flammation in AA pathogenesis.
Mesenchymal stem cells (MSCs) are adult somatic
cells that reside in the stroma of solid organs, and have
been demonstrated to differentiate into a variety of cell
types including: osteoblasts, chondrocytes, and adipocytes
[12]. Recently, MSCs have been shown to have anti-
inflammation effects, and have been applied for treating
immune/inflammation associated disorders such as sep-
sis [13], graft versus host disease [14], and experimental
colitis [15]. We previously demonstrated that intra-
abdominal implantation of BM-MSCs sheet by laparotomy
could attenuate the development of angiotensin II (AngII) -
induced AA in apolipoprotein E-deficient (apoE−/−) mice
by anti-inflammation [16]. However, this approach re-
quires surgery to deliver BM-MSCs, and may be invasive
to patients. Intravenous delivery of BM-MSCs offers an
attractive approach, because it is simple, less invasive
and is a repeatable administration of a large numbers of
cells. The property of BM-MSCs mobilizing or homing
into sites of tissue damage or inflammation raises the
possibility of intravenous administration of BM-MSCs
for treatment of AA [17].
Therefore, in this study, we investigated the effects
of intravenous administration of BM-MSCs on AngII-
induced AA formation in apoE−/− mice.Methods
Animal
ApoE−/− mice (genetic background C57BL/6) were obtained
from the Jackson Laboratory (Sacramento, California) and
maintained on a regular chow diet under standard condi-
tions. All animal experiments were performed in accordance
with the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH pub-
lication No. 85–23, revised 1996), and approved by the
Animal Care and Use Committee of Nagoya University
(protocol No. 24061).Isolation, culture, and differentiation of bone marrow-derived
mesenchymal stem cells
BM-MSCs were isolated from femurs and tibiae of male
apoE−/− mice (6 to 8 weeks old) and expanded as de-
scribed [18]. The mesenchymal population was isolated
on the basis of its ability to adhere to the culture plate.
At 90% confluence, the cells were trypsinized (0.05%
Trypsin containing 0.53 mM EDTA-4Na, Invitrogen) and
were passaged to 175-cm2 flasks. Expansion culture con-
tinued up to passages 7–10 were used in all experiments.
Cultured BM-MSCs were incubated with the follow-
ing antibodies, conjugated with phycoerythrin (PE),
allophycocyanin (APC) or peridinin chlorophyll protein-
Cy5.5 (PerCP-Cy5.5) (eBioscience): CD11b, CD31, CD34,
CD44, CD45, CD73, CD106, CD117, and Sca-1. Labeled
cells were assayed by flow cytometer (FACS Canto II,
Becton Dickinson) and analyzed with BD FACSDiva
Software and FlowJo (Tree Star Inc.). The capacity to
differentiate into osteogenic, adipogenic, and chondrogenic
lineages by addition of inductive media was con-
firmed with chemical staining as performed previously
(Additional file 1) [18].AA model and MSCs transplantation
Ang II induced aortic aneurysm model in apoE−/− mice
were used in this study. Male apoE−/− mice (24 to 28
weeks old) were infused with 1000 ng/kg/min Ang II
(Calbiochem, CA, USA) for 28 days. Ang II was infused
using Alzet osmotic pumps (DURECT, Cupertino, Calif,
Model 2004). Mice were anesthetized with Isoflurane,
delivered using a calibrated vaporizer equipped with an
induction chamber and a nose cone, and administered at
2-5% in O2 (2 L/min). It was then decreased to 2% to
maintain anesthesia. Anesthesia was monitored by pinching
the toe. Pumps were implanted subcutaneously in the back
in the prone position through a small incision that was
closed with suture.
The apoE−/− male mice were divided randomly into
three groups: (1) a sham group (group Sham, n=10),
mice without Ang II infusion or BM-MSCs administra-
tion, (2) a control group, mice with Ang II infusion and
saline injection (group CONT, n=10), (3) and a MSCs
treatment group, mice with Ang II infusion and multiple
BM-MSCs intravenous administration (group MSC4, n=12).
Because the effects of a single intravenous administration
of BM-MSCs (group MSC1, n=10) were modest in our
preliminary experiments (Additional files 2, 3, 4, 5), we
established multiple BM-MSCs administration with the
same dosage of cells (1×106 MSCs in 0.2 ml saline), or
0.2 ml saline was injected weekly into apoE−/− mice via
tail vein at the time of Alzet osmotic pump implantation.
Mice were intravenously administered BM-MSCs or saline
four times totally (Figure 1A).
Figure 1 Multiple intravenous administrations of BM-MSCs inhibited AngII-induced aortic aneurysm (AA) formation in apoE−/− mice.
A) Schematic diagram of study design. B) Representative macroscopic images of aorta from group Sham, CONT, and MSC4. Arrowheads
indicate typical AAs induced by Ang II in apoE−/− mice. C) Incidence of Ang II-induced AA was significantly decreased in group MSC4
compared with group CONT. There was no AA formation in group Sham. D-F) Aortic outer diameters measured at ascending, phrenic, and
infrarenal levels in apoE−/− mice. Data are presented as means ± SEM (n =10-12) **P<0.01, ***P<0.001 vs. group CONT, assessed by chi-square
test (for AA incidence) and one-way ANOVA (for aortic diameter).
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MSCs on the day of transplantation were labeled with
fluorescent dyes using a PKH26 red fluorescent cell
linker kit (Sigma-Aldrich, St. Louis, MO), as reported
previously [19].
Aortic diameter measurement and specimen preparation
Twenty-eight days after pump implantation, all animals
were euthanized by pentobarbital overdose. The aorta
from ascending to the iliac bifurcation was dissected free
from the surrounding connective tissue. The outer aortic
diameters at the level of the ascending aorta, the abdom-
inal aorta of the phrenic neck, and the abdominal aortaat the infrarenal proximal neck site were obtained with a
calibrated ocular grid, as described previously [20]. Im-
ages of aorta were recorded with a digital camera and
analyzed with ImageJ software (NIH).
A commonly used clinical standard to diagnose abdom-
inal aortic aneurysm is an increase in aortic diameter
of ≈50% [21]. The average diameter of normal suprarenal
aorta in naïve control mice is ≈0.8 ± 0.01 mm. We there-
fore set a threshold of 1.25 mm as evidence of the inci-
dence of aneurysm formation.
The aorta from the ascending aorta to the iliac bifur-
cation was then dissected away, and a 2-mm length of
suprarenal aorta was cut for histologic examination. The
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quantification, zymography, and enzyme-linked immuno-
sorbent assay (ELISA).
Measurement of elastin content in aortic tissue
Elastin was isolated as previously described [22]. The
elastin amounts of aortas from apoE−/− mice were quan-
tified using a Fastin elastin assay kit (Biocolor, County
Antrim, UK) according to the manufacturer’s protocol.
Briefly, the dissected aortic tissues were weighed and cut
into pieces with fine scissors. To convert insoluble elas-
tin to water soluble alpha-elastin, approximately 1 mg
(dry weight) of samples were placed with 300 μL of
0.25 M oxalic acid into a metal heating block with the
thermostat set at 100°C for 60 min. The samples were
then centrifuged at 3,000 × g for 10 min and 250 μL of
the supernatant was retained in a new container with
250 μL of elastin precipitating reagent. The tubes were
centrifuged at 10,000 × g for 10 min and the superna-
tants discarded, followed by adding 1.0 mL of the dye
reagent, and were placed in a mechanical shaker at
room temperature for 90 min. Subsequently, the tubes
were centrifuged at 10,000 × g for 10 min and the su-
pernatants discarded. Two-hundred fifty μL of dye
dissociation reagent was added to the elastin-bound
dye pellet to release the bound dye into solution. Aliquots
of each sample (250 μL) were transferred to the wells of
a 96-well plate and the optical density was measured at
513 nm. Elastin values were standardized to the corre-
sponding dry-weight.
Gelatin zymography
Gelatin zymography was performed to evaluate MMP-2
and MMP-9 enzymatic activities in aortic tissues as
described previously [23]. Briefly, the aortic tissues
in vivo were homogenized with a protein extraction
buffer containing 20 mM Tris–HCl (pH 7.5) and 0.01%
Brij-35 (MP Biomedicals, CA, USA). The protein concen-
tration in each lysate was measured using a BCA assay kit
(PIERCE, Rockford, IL, USA). Forty μL of an equal con-
centration of protein (0.2 mg/mL) was applied to the
samples for electrophoresis, and was detected using a
Gelatin Zymography electrophoresis kit (Life Kenkyusho,
Yamagata, Japan) according to the manufacturer’s
protocol. To quantitatively assess the intensity of bands
for MMPs quantitatively, densitometric analysis was
performed using Digi Print Doc (Bio tools, Gunma, Japan)
with imaging Quant TL (GE Healthcare, Bucks, UK).
Histology and immunofluorescence staining
Suprarenal aortas from each group were embedded in
OCT compound (Tissue-Tek, Miles Inc., IN, USA).
Specimens were cut into 5-mm cross-sections, and stained
with Elastica Van Gieson (EVG) for elastin fibers. Foridentifying macrophages in the aortic wall in vivo, rat
anti-mouse polyclonal antibody against F4/80 (1:100,
AbDSerotec, Oxford, UK) was used, and the secondary
antibody Alexa, Fluor 488 conjugated anti-rat IgG (H+L)
(1:1,000, Cell Signaling Technology, Boston, MA, USA)
was used for detection. Nuclei were stained with 40,
6-diamidino-2-phenyindole, DAPI (Vector Laboratories,
Burlingame, CA, USA). Slides were examined with
Olympus IX51 microscope and images captured using
DP2-BSW software (Olympus, Tokyo, Japan). Quantifi-
cation of F4/80 staining area was performed by two
blinded investigators in 10 randomly selected areas and
subsequently averaged using the Image-Pro Plus version
4.1 software (Media Cybernetics, Inc., MD).
Quantitative protein expression of aortic tissue
The quantitative expression of protein including MMP
inhibitors (TIMP-1 and −2), chemokine (MCP-1), cyto-
kines (IL-1ß, IL-6, and TNF-α), and growth factors (IGF-1
and TGF-ß1) was determined by enzyme-linked immuno-
sorbent assay (ELISA) as described previously [23]. Aortic
tissues were homogenized in protein extraction buffer
(CytoBusterTM; Novagen, Merck KGaA, Darmstadt,
Germany) with 20 mM EDTA (Dojindo, Kumamoto,
Japan) and 1 mM PMSF (Thermo, Fisher Scientific,
MA, USA). The protein concentration for the lysate was
measured using a BCA assay kit (Pierce). An equal con-
centration of total protein was applied to samples for
each plate and detected according to the manufac-
turer’s protocol of each ELISA kit (IGF-1; Mediagnost,
Reutlingen, Germany, TGF-ß1, TIMP-1; R&D Systems,
Minneapolis, MN, USA, TIMP-2; RayBiotech, Norcross,
GA, USA, IL-1ß, IL-6, TNF-α and MCP-1; Bender
MedSystems, Vienna, Austria).
Statistical analyses
Data analyses were performed with GraphPad Prism for
Mac (Version 4, San Diego, CA, USA). Results were
expressed as mean ± SEM. Statistic comparison for the
incidence of AA was performed by chi-square test. Multiple
comparisons of mean values were performed by a one-way
factorial analysis of variance (ANOVA), and unpaired
t-tests. Statistical significance was defined as P<0.05.
Results
BM-MSCs inhibited the development of AA in Ang II-infused
apoE−/− mice
To determine the effects of intravenous administration
of BM-MSCs on Ang II-induced AA formation, AngII-
infused apoE−/− mice received multiple intravenous
administrations of BM-MSCs or saline via tail vein.
Figure 1B shows representative images of aortas from
each group. The incidence of the development of AA in
group CONT was 100%, which was significantly decreased
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outer diameter at the ascending, phrenic, and infrarenal
level in each group was measured. At those three levels,
group CONT mice showed a significantly larger aortic
diameter compared with group Sham. Treatment with
BM-MSCs resulted in significantly decreased aortic di-
ameters compared with group CONT at the levels of as-
cending and infrarenal, but not at the phrenic level
(Figure 1D-F). These results indicated that AngII infu-
sion for 28 days in apoE−/− mice induced AAs and that
this process could be effectively inhibited by multiple
intravenous administrations of BM-MSCs.
BM-MSCs suppressed aortic elastin degradation in
AngII-infused apoE−/− mice
EVG-stained sections from suprarenal aortas of group
Sham showed normal wavy elastic lamina structure in
the aortas, but sections from group CONT showed dis-
ruption of elastic fibers and aneurysm formation. Intra-
venous administration of MSCs partially maintained the
wavy structure of the elastic lamellae (Figure 2A-C). In
addition, elastin volume of the aortic tissues was mea-
sured. The elastin content of the aorta in group MSC4Figure 2 Multiple intravenous administrations of BM-MSCs attenuate
normal wavy elastic lamina structure in group Sham, and B) disruption of elas
BM-MSCs maintained wavy structure of the elastic lamellae. Scale bar = 200 μ
significant decrease in group CONT compared with group Sham, but preserv
**P<0.01, ***P<0.001 vs. group CONT, assessed by one-way ANOVA.was significantly increased compared with group CONT,
and showed no significant difference compared with group
Sham (group MSC4 vs. group CONT, 39.69 ± 7.65 vs
24.80 ± 2.78, μg/mg, P < 0.01; group MSC4 vs. group
Sham, 39.69 ± 2.21 vs. 48.35 ± 3.28, μg/mg, P > 0.05;
Figure 2D).
BM-MSCs decreased inflammatory response in AngII-infused
apoE−/− mice
Immunofluorescence staining demonstrated that F4/80-
positive macrophages were detected abundantly in the
adventitia and media of the suprarenal aortic walls of
group CONT. The macrophages infiltration was amelio-
rated by BM-MSCs administration (Figure 3 A-E). Quan-
titation of the area of F4/80 staining as a ratio of the DAPI
staining area was shown in Figure 3 J.
BM-MSCs suppressed MMP-2 and MMP-9 activity in
AngII-infused apoE−/− mice
Gelatin zymography was conducted to evaluate MMP-2
and -9 enzymatic activities in the aortic tissues. A repre-
sentative zymogram was shown in Figure 4A. Quantita-
tion of the band intensity shows that (pro- and active-)d aortic elastin degradation in apoE−/− mice. A) EVG staining shows
tic lamina and aneurysm formation in group CONT. C) Administration of
m. D) Measurement of elastin volume of aortic tissues showed a
ation in group MSC4. Data are presented as means ± SEM (n =10-12)
Figure 3 Multiple intravenous administrations of BM-MSCs suppressed macrophage infiltration in aortic tissues. A-I) Representative F4/80
immunofluorescence stained sections of suprarenal aortas from Sham, CONT, and MSC4 groups. Arrowheads indicated F4/80 macrophages. Scale
bars=100 μm. J) Quantitation of F4/80- positive macrophages area as a ratio of the DAPI staining area. Data are presented as means ± SEM (n =10-12)
**P<0.01, ***P<0.001 vs. group CONT, assessed by one-way ANOVA.
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significantly decreased in group MSC4 compared with
group CONT (Figure 4B-E).
BM-MSCs regulated aortic cytokines, chemokine, and
growth factors expression
Protein expression including MMP inhibitors (TIMP-1
and TIMP-2), chemokine (MCP-1), proinflammatory cy-
tokines (IL-1ß, IL-6, and TNF-α), and growth factors
(IGF-1 and TGF-ß1) was evaluated by ELISA. There wereno statistical differences in TNF-α expression between
group CONT and group MSC4, while expressions of
IL-1β, IL-6, and MCP-1 that promote inflammatory
reaction were significantly decreased in group MSC4
compared with group CONT (Figure 5A-D). At the
same time, the expression of IGF-1 and TIMP-2 which
promote elastin synthesis were significantly increased
in group MSC4 compared with group CONT, though
expression of TGF-β1 and TIMP-1 showed no signifi-
cant difference (Figure 5E-H).
Figure 4 Gelatin zymography of MMPs activities in aortic tissues. A) Gelatin zymography of 4 representative specimens from positive
control (from kit), and Sham, CONT, and MSC4 groups. B-E) Zymographic band densities from all tissue samples were quantified by densitometry.
Enzyme activities of (pro- and active-) MMP-2 and MMP-9 were significantly decreased in group MSC4 compared with group CONT. The enzyme
activities of MMPs are expressed as a mean ±SEM (n =10-12). *P < 0.05. ***P <0.001 vs. group CONT, assessed by one-way ANOVA. MMPs,
matrix metalloproteinases.
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We investigated whether intravenous injected BM-MSCs
mobilized into the aortic walls. BM-MSCs were labeled
with fluorescent PKH26 and then intravenously injected
into the apoE−/− mice via tail vein. PKH26 labeled BM-
MSCs were detected in the media and adventitia of aor-
tas four weeks after operation (Figure 6).
Discussion
In the present study, we demonstrated that intravenously-
administered BM-MSCs were capable of engrafting into
the aortic wall in Ang II-infused apoE−/− mice, and thatmultiple intravenous administrations of BM-MSCs could
effectively: (1) reduce the incidence of AA, (2) suppress
both inflammatory reaction and elastin degradation in
aortic tissues, and (3) inhibit MMP-2 and MMP-9 activ-
ities in the aortic tissues. Here, for the first time, we
showed that multiple intravenous administrations of
BM-MSCs were effective for prevention of Ang II-induced
AA in apoE−/− mice.
Ang II-induced AA in apoE−/− mice provides a model
that resembles human AA. Ang II promotes vascular
inflammation characterized by macrophage infiltration
in the vascular wall [24,25]. Macrophages are a major
Figure 5 ELISA analyses of inflammatory cytokines (IL-1β, IL-6, and TNF-α), chemokine (MCP-1), tissue inhibitor of metalloproteinases
(TIMP-1 and TIMP-2), and growth factors (IGF-1 and TGF-β1) in aortic tissues 4 weeks after operation. Intravenously administered BM-MSCs
reduced IL-1β (A), IL-6 (B), and MCP-1 (D) but did not significantly alter expression of TNF-α (C). BM-MSCs also increased expressions of IGF-1 (E), and
TIMP-2 (H) but did not alter expressions of TGF-β1 (F) and TIMP-1 (G). All data are presented as mean ± SEM (n =10-12). *P < 0.05, **P < 0.01,
and ***P < 0.001 vs. group CONT, assessed by unpaired t-test. IL, interleukin; TNF, tumor necrosis factor; MCP, monocyte chemotactant protein;
TGF-β, transforming growth factor β; IGF-1, insulin-like growth factor; TIMP, tissue inhibitor of metalloproteinase.
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degrade the extracellular matrix and impair the struc-
tural integrity of the vascular wall, leading to AA forma-
tion [25]. On the other hand, it has been reported that
activated macrophages produce a number of proapoptotic
mediators, which result in apoptosis of SMCs [26]. Thus,
vascular inflammation, which triggers both vascular wall
proteolysis and SMCs apoptosis, could result in an im-
balance between extracellular matrix degradation and
synthesis, favoring tissue destruction and AA formation.
Accumulating evidence indicates that anti-inflammationis a promising therapeutic strategy for AA [4]. MSCs
reportedly have anti-inflammation activities [27]. This
anti-inflammatory effect of MSCs could inhibit both
the proteolytic and proapoptotic pathways, thus restor-
ing the balance between matrix synthesis and degrad-
ation, thereby improving tissue repair.
We previously reported that intra-abdominal implant-
ation of BM-MSCs sheets by laparotomy inhibited the
development of Ang II-induced aortic aneurysm in
apoE−/− mice by anti-inflammation and elastin preserva-
tion [16]. However, BM-MSCs implantation by laparotomy
Figure 6 Tracking of transplanted PKH26 labeled BM-MSCs in the aortic walls. A) Representative aortic sections from group CONT. B) Representative
aortic sections from group MSC4. Four weeks after operation, PKH26-positive BM-MSCs were mainly observed in the adventitia of aorta in group MSC4.
Arrows point to sites of BM-MSC. At least three random aortic cross sections per mouse were chosen for evaluation. PKH26 (red), DAPI (blue),
Scale bars = 100 μm.
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needed. Numerous experimental studies have shown that
intravenous delivery of MSCs is an effective approach for
treatment of a variety of diseases such as myocardial infarc-
tion [28], stroke [29], lung injury [30], and diabetes mellitus
[31]. Moreover, it is considered a suitable route for transla-
tion into clinical application, due to its low invasiveness.
In the present study, we investigated the effects of intra-
venous administrations of BM-MSCs on AngII- induced
AA formation in apoE−/− mice. In our preliminary experi-
ments we found that the effects of single intravenous
administration of BM-MSCs were modest (data was shown
in additional figures), then we focused on multiple
intravenous administrations of BM-MSCs. Our results
demonstrated that multiple intravenous administrations
of BM-MSCs significantly reduced the incidence of
Ang II-induced AA in apoE−/− mice.
Consisted with our previous study, we found that
multiple intravenous administrated BM-MSCs suppressed
infiltration of macrophages and activities of MMPs in
the aortic walls. BM-MSCs also markedly decreased
proinflammatory cytokines secretions including IL-1β,
IL-6, and MCP-1, while increasing growth factor ex-
pressions like IGF-1 and TIMP-2, which promote elas-
tin synthesis. These results suggested that the effects
of multiple intravenous administrated BM-MSCs on
Ang II-induced AA in apoE−/− mice may be associated
with anti-inflammatory actions.
It should be noted that in this study multiple intravenous
administrations of BM-MSCs effectively inhibited develop-
ment of AngII-induced AA in apoE−/− mice, while single
intravenous administration of BM-MSCs showed modest
effects. We presumed that the timing and cell dose of BM-
MSCs might account for the different results. BM-MSCswere shown to be able to migrate into sites of inflammation
or injury when transplanted locally or systemically [32],
which was believed to be mediated by chemotactic proteins
such as MCP-1, and IL-8 secreted from injured or inflam-
matory tissues [33]. The timing of single BM-MSCs injec-
tion in this study was just after pump implantation, and at
that time aortic inflammation did not occur. On the other
hand, we intravenously administrated 4×106 BM-MSCs for
each mouse in multiple injection group while 1×106 in
single injection group. The different cell dose may affect
the strength of anti-inflammatory effects of BM-MSCs.
The appropriate timing and cell dose for intravenous
administrations of BM-MSCs treatment of AA remain
unclear. Further studies are currently under investiga-
tion by our group.
There are several limitations to the present study.
First, the BM-MSCs population used in this experiment
may be mixed, rather than limited to BM-MSCs, al-
though cell surface markers of cultured cells were consist-
ent with those previously reported [18]. Second, although
we observed the effects of multiple intravenous adminis-
trations of BM-MSCs 4 weeks after operation, the long-
term effects remain unclear, and further experiment is
needed. Third, we used a model of Ang II-induced AA in
apoE−/− mice, further experiments using other AA models
are needed to confirm the effects of multiple intravenous
administrations of BM-MSCs.
Conclusions
Multiple intravenous administrations of BM-MSCs were
effective to suppress inflammatory reactions in Ang II-
infused apoE−/− mice, and inhibit the development of
AAs. It may therefore serve as a new therapeutic strategy
for patients with AA.
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Additional file 1: Figure 1. Characterization of BM-MSCs. A) Morphology
of BM-MSC. Scale bar=100 μm. B-D) Multipotency of BM-MSCs. BM-MSCs
differentiated into osteocytes (B), adipocytes (C), and chondrocytes (D).
Scale bars=100 μm. E) Flow cytometric analysis of BM-MSCs.
Additional file 2: Figure 2. Single intravenous administration of BM-MSCs
did not inhibit Ang II-induced aortic aneurysm formation in apoE−/−
mice. A) Incidence of Aortic aneurysm. B-D) Aortic outer diameters
measured at ascending, phrenic, and infrarenal levels in apoE−/− mice.
Data are presented as means ± SEM (n =10-12) **P<0.01, ***P<0.001 vs.
group CONT, assessed by chi-square test (for AA incidence) and one-way
ANOVA (for aortic diameter).
Additional file 3: Figure 3. Single intravenous administration of BM-MSCs
did not attenuate aortic elastin degradation in apoE−/− mice. A) EVG staining
of suprarenal aortas and B) elastin volume of aortic tissues. Data are
presented as means ± SEM (n =10-12) ***P<0.001 vs. group CONT,
assessed by one-way ANOVA.
Additional file 4: Figure 4. Single intravenous administration of BM-MSCs
did not suppress macrophages infiltration in aortic tissues. Representative
F4/80 immunohistochemical (A- I) stained sections of suprarenal aortas
from Groups Sham, CONT, and MSC1. Scale bars=100 μm. J) Quantitation of
F4/80-positive macrophages. Data are presented as means ± SEM (n =10-12)
**P<0.01, ***P<0.001 vs. group CONT, assessed by one-way ANOVA.
Additional file 5: Figure 5. Gelatin zymography of MMPs activities in
aortic tissues. (A-D) Zymographic band densities were quantified by
densitometry. Enzyme activities (pro- and active-) of MMP-2 and MMP-9
are expressed as a mean ±SEM (n =10-12). ***P < 0.001 vs. group CONT,
assessed by one-way ANOVA. MMPs, matrix metalloproteinases.
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